OCS Oculis Holding AG

$OCS Smells like tax loss selling. Near term catalysts are sort of boring, but I think completion of enrollment (later this quarter?) of PREDICT-1 Licaminlimab for DED will be regarded as positive and stop the price decline. This is a good chance Licaminlimab meets it's trial goals, so the stock will not be cheap after that. I'll buy some in early november if I can find the cash. That's when I think the stock price will near a low.

$OCS On September 10, due to a clear downtrend, I sold my small starter position in OCS for $11.34 for a loss of $0.02 per share. I came to the conclusion that OCS will likely continue to drop in price until the end of tax-loss selling this year. The only slightly-positive catalyst I see for late 2026 is finishing enrollment of PREDICT-1 Licaminlimab for DED. Other events possible in 2026 would be starting of the PIONEER-2 and PIONEER-3 trials. However, these events may be viewed negatively by the market, as they increase quarterly expenses, reducing their cash runway. Filing of the IND for MS relapse should also happen in 2026, but that event should be neutral. It is expected and has no immediate financial effect. December of 2026 should be a better time to accumulate to anticipate positive data of Licaminlimab for DED around 2026-06. For me, positive results seem likely due to targeting of the TNFR1 genotype. Long term, I am very bullish on OCS, but at the right entry price.